Hypomagnesemia and Its Clinical Outcome

NCT07089004 | Completed DMC

• 2 other identifiers: BBMH/2023/RP-2342BBMH/June/2023/011
• Study Type: observational
• Target: 112
• Locations: 1 country
• Sites: 1

Brief Summary

Magnesium is an essential electrolyte involved in numerous physiological processes, including maintaining cellular integrity, regulating muscle tone, supporting cardiovascular function, and modulating immune responses. Despite its critical role, magnesium is often overlooked in clinical practice, earning it the title of the "forgotten electrolyte." Hypomagnesemia, defined as serum magnesium levels below 1.5 mEq/L, has been associated with adverse clinical outcomes such as increased mortality, prolonged ICU stays, and higher requirements for mechanical ventilation. Critically ill patients are particularly vulnerable to hypomagnesemia due to various underlying conditions, gastrointestinal losses, and renal complications. However, limited data are available from Bangladesh on the burden and clinical impact of hypomagnesemia in ICU settings. This study aims to assess the correlation between hypomagnesemia and clinical outcomes, including length of ICU stay, need for mechanical ventilation, and mortality among critically ill patients in a tertiary care ICU in Bangladesh.

Conditions

Hypomagnesemia; Critical Illness; Intensive Care Unit (ICU) Patients; Scoring Systems

Outcome Measures

Primary Outcomes (1)

• Association of Hypomagnesemia with ICU Mortality

  To assess the relationship between low serum magnesium levels and all-cause mortality among critically ill ICU patients.

  From the date of ICU admission until the date of ICU discharge or death, assessed up to 60 days.

Interventions

No intervention (observational study) DIAGNOSTIC_TEST

Observational - Biochemical, Hematological and Clinical Scoring Assessments

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Population will consist of critically ill adult patients admitted to the Intensive Care Unit (ICU) of a tertiary care hospital in Bangladesh. The study will include both male and female patients aged 18 years and above, irrespective of their underlying diagnosis, provided they meet the inclusion criteria. Patients will be assessed for serum magnesium levels (Hypo; Normo and Hyper) within 24 hours of ICU admission, along with relevant biochemical, hematological and clinical parameters. The study will exclude individuals with known end-stage renal disease on dialysis, those receiving magnesium supplementation prior to ICU admission, pregnant women and patients with incomplete medical records.

You may qualify if:

• Patients aged 18 years and above.
• Patients admitted to the Intensive Care Unit (ICU).
• Patients who have serum magnesium levels measured within 24 hours of ICU admission.

You may not qualify if:

• Patients with known end-stage renal disease on dialysis.
• Patients with a history of magnesium supplementation prior to ICU admission.
• Pregnant women.
• Patients with incomplete medical records or unavailable laboratory data.

Sponsors & Collaborators

• Bangladesh Bioscience Research Group: lead
• Chattogram International Dental College: collaborator
• Chittagong Medical College and Hospital: collaborator
• Bangladesh Medical University: collaborator

Study Sites (1)

University of Science and Technology Chittagong (USTC)

Chittagong, Khulshi, 4202, Bangladesh

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Blood: Serum/Plasma Samples were collected from critically ill patients admitted to the Intensive Care Unit (ICU). The retained biospecimen will include serum samples, which will be used to measure serum magnesium levels and other relevant biochemical parameters as part of routine clinical assessment and research analysis.

MeSH Terms

Conditions

Critical Illness

Condition Hierarchy (Ancestors)

Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Target Duration: 1 Day
• Sponsor Type: NETWORK
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Lab-Incharge (Biochemist)

Study Record Dates

• First Submitted: June 29, 2025
• First Posted: July 28, 2025
• Study Start: June 1, 2024
• Primary Completion: December 31, 2024
• Study Completion: April 25, 2025
• Last Updated: July 28, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will not share

Locations

BA (1)